In general, oral mucositis (OM) occurs in up to 20% to 65% of adult cancer patients receiving conventional chemotherapy for solid tumours, up to 80% of patients receiving high-dose chemotherapy for haematopoietic stem cell transplantation (HSCT), and almost all patients receiving radiotherapy for head and neck cancer.[4]Jones JA, Avritscher EB, Cooksley CD, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun;14(6):505-15.
http://www.ncbi.nlm.nih.gov/pubmed/16601950?tool=bestpractice.com
[5]Vera-Llonch M, Oster G, Ford CM, et al. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007 May;15(5):491-6.
http://www.ncbi.nlm.nih.gov/pubmed/17139495?tool=bestpractice.com
[6]Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006 Jan 15;106(2):329-36.
https://onlinelibrary.wiley.com/doi/10.1002/cncr.21622/full
http://www.ncbi.nlm.nih.gov/pubmed/16342066?tool=bestpractice.com
The risk of OM after conventional chemotherapy for solid tumours is known to be associated with treatment regimen. One meta-analysis reported an OM incidence of 65% in patients with breast cancer treated with docetaxel plus doxorubicin plus cyclophosphamide (TAC), with severe OM occurring in 5%.[4]Jones JA, Avritscher EB, Cooksley CD, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun;14(6):505-15.
http://www.ncbi.nlm.nih.gov/pubmed/16601950?tool=bestpractice.com
Among patients with lung cancer treated with platinum agent- or gemcitabine-based regimens, OM incidence was 15%, with severe OM reported in 1%. OM was reported in 14% of patients with colon cancer treated with fluorouracil-based chemotherapy, with severe OM occurring in 1.7%.
For HSCT, the severity of OM is associated with transplant type and conditioning regimen. One multi-centre study investigating OM incidence in patients undergoing HSCT reported that 71% were diagnosed with OM and 21.6% with severe OM following transplant.[7]Vagliano L, Feraut C, Gobetto G, et al. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT-results of a multicentre study. Bone Marrow Transplant. 2011 May;46(5):727-32.
http://www.ncbi.nlm.nih.gov/pubmed/20818449?tool=bestpractice.com
The risk of severe OM was greater among adult patients receiving allogeneic HSCT compared with autologous HSCT (39.7% and 16.4%, respectively; P <0.001). In one systematic review investigating OM among allogeneic HSCT patients, severe OM occurred in 71.5% of patients treated with reduced-intensity regimens and in 79.7% of patients treated with myeloablative regimens (P <0.01).[8]Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant. 2016 Apr;22(4):605-16.
https://www.astctjournal.org/article/S1083-8791(15)00639-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/26409924?tool=bestpractice.com
OM is an extremely common adverse effect of radiotherapy for head and neck cancer, occurring in virtually all patients.[3]Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1110-20.
http://www.ncbi.nlm.nih.gov/pubmed/17398022?tool=bestpractice.com
[9]Liu M, An R, Wu Z, et al. The trajectory of oral mucositis in head and neck cancer patients undergoing radiotherapy and its influencing factors. Ear Nose Throat J. 2024 Feb 9:1455613241228211.
https://journals.sagepub.com/doi/10.1177/01455613241228211
http://www.ncbi.nlm.nih.gov/pubmed/38334289?tool=bestpractice.com
[10]Iovoli AJ, Turecki L, Qiu ML, et al. Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2337265.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810484
http://www.ncbi.nlm.nih.gov/pubmed/37819659?tool=bestpractice.com
Frequency and severity is influenced by several factors including tumour site, radiation field and technique, and the use of concomitant chemotherapy.[11]Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022 Jan;72(1):57-77.
https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21704
http://www.ncbi.nlm.nih.gov/pubmed/34714553?tool=bestpractice.com
In one cohort study examining patient-reported OM after treatment with intensity-modulated radiotherapy, 62.5% of patients were found to have severe OM.[10]Iovoli AJ, Turecki L, Qiu ML, et al. Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2337265.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810484
http://www.ncbi.nlm.nih.gov/pubmed/37819659?tool=bestpractice.com